🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. mitoxantrone hydrochloride

    Karyopharm Therapeutics Inc

    Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

    phase 1 small molecule completed

    1 trial

  2. mitragynine

    BRIGHT MINDS BIOSCIENCES INC.

    Safety and Tolerability in Healthy Subjects

    phase 1 small molecule active

    1 trial

  3. namilumab (MT203)

    Takeda

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  4. narfurine hydrochloride orally disintegrating tablets

    The First People's Hospital of Lianyungang

    Improvement of Pruritus in Hemodialysis Patients

    phase 1 small molecule active

    1 trial

  5. nesvacumab (REGN910/ SAR307746)

    Regeneron UK Limited

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  6. ombrabulin (AVE8062)

    Sanofi Pasteur

    Neoplasms, Malignant

    phase 1 small molecule completed

    1 trial

  7. pyroglutamate rongliflozin capsules

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetes Mellitus, Type 2

    phase 1 small molecule completed

    1 trial

  8. pyroglutamate rongliflozin capsules

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  9. removal of omentum

    United Therapeutics Europe Ltd

    Diabetes Mellitus Type 2

    phase 1 other completed

    1 trial

  10. sabirnetug (ACU193)

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  11. salvianolic acid A

    The First People's Hospital of Lianyungang

    Diabetes

    phase 1 small molecule active

    1 trial

  12. sarilumab SAR153191 (REGN88)

    Sanofi Pasteur

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  13. selonabant

    Anebulo Pharmaceuticals

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  14. sphingosine kinase-2 inhibitor ABC294640

    Apogee Therapeutics

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  15. standard dose capecitabine

    Karyopharm Therapeutics Inc

    Rectal Neoplasms

    phase 1 small molecule active

    1 trial

  16. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  17. vadadustat reference tablets

    Akebia Europe Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  18. zimberelimab

    Arcus Biosciences

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  19. ​​A Phase 1, Open-Label, Multiple-Part Trial to Evaluate the Drug-Drug Interaction Potential of PRAX-628 in Healthy Participants​

    Chongqing Precision Biotech Co., Ltd

    Epilepsy

    phase 1 other active

    1 trial

  20. ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​

    Amgen

    microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

    phase 1 other active

    1 trial

  21. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  22. 0.9% Sodium Chloride Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unstable Angina

    approved small molecule active

    1 trial

  23. 18F-Canagliflozin, Invokana 300 mg film-coated tablets

    Disc Medicine

    Chronic Kidney disease

    approved small molecule active

    1 trial

  24. 37.5mg Pregabalin + 75mg Pregabalin

    The First People's Hospital of Lianyungang

    Pain, Postoperative

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources